今天低开在3273，最低3270，最高3298，收盘在3291。个股涨跌家数比4363：875，普涨。 今天在面临日级别有调整要求的情况下，不仅创了反弹新高，还攻击了3300附近的颈线位3297，可以说总体上是表现不错的，不得不说这是面对3439调整 以来形成的下降趋势线多头主力势在必得的一种态度，因为一旦在此处犯怂的话，那就很可能被空头借力发动一波反扑。总的来说，在上周五盘后多头优 势已很微弱的局面下，多头大资金（那只"无形之手"）今天这一仗打得还是很漂亮的，调动了量化的助力。 从盘中表现来看，攻击3300附近回落后基本上是在3285横盘振荡的，这也是我直播里非常希望看到的局面。而从个股来说，大票先带领攻击了一波，后面 也是我直播里希望出现的大票歇脚小票开始表现，挺好，可以让小散们回点血，这对凝聚人气是好处多多的。再有一点就是成交量，这是周评里特别强调 的能否突破下降趋势线的关键因素，在技术面有调整要求的情况下，要想继续上攻，那必须由成交量推动才能实现，而今天是在缺少北向资金的情况下放 出来的，很难得啊。 短期而言，一旦量能不济短调随时会来。继续关注3300附近和10日线的得失即可。 中期态势：已见底，转好 ...

前一交易日收评：日级别有调整要求，继续关注3300附近的压力和10日线的支撑 早盘低开，未见向下之意，见了向上之意。个股涨多跌少。早盘分型定式大盘和创指均为收阳（午后见盘中新低才会被扭转）。 前一交易日收盘点评"今天全天振荡，收盘结果仍是多头掌控短期主导权。目前日级别有调整要求，短期来说站稳3260一线转好可能性才会增 大，站上3300才有转强可能，突破3342才能转强，3240一线已不宜再失。近日可重点关注3300附近的压力和10日线的支撑"。早盘小幅低开高 走，再攻之意明显，在3300附近出现犹豫，在此处想要突破是需要成交量推动才行的，若量能不济回落难免，盘中突破了3439调整以来形成的 下降趋势线，今若能确保收上3285就是突破该线之相了，重点看收盘结果吧。午后，在3270-3274之上才行，在3280-3285之上才好，冲击3297- 3307才强，不宜跌下3265-3261，不可失守3258-3250。操作上，上下俩缺口间振荡，反复做T；先补上面，看多；先补下面，看空。 短线技术面：今天日生命线在3276附近，运行在其上才能看多。大盘日级别关键区域目前3272－3307，在上沿之上运行才是强势，才会 ...

Core Viewpoint - The current market situation is characterized as neither bullish nor bearish, with a mid-term downtrend but a short-term bullish advantage. The decision on market direction may depend on external factors rather than just technical indicators [1][5]. Technical Analysis - The market needs to close above 3310 to be acceptable, above 3330 for a positive outlook, and above 3350 for a strong bullish signal. A close above 3290 is necessary for stability [2][9]. - The weekly chart shows a small bullish candle with a closing price of 3276, indicating a 1.19% increase. However, the mid-term outlook remains negative while the short-term shows slight bullishness [2][4]. - The weekly technical indicators suggest a mid-term downtrend, with MACD lines diverging downwards and KDJ lines showing a bearish crossover. The market is currently below key moving averages [4][8]. - A breakthrough of the downtrend line is possible if the trading volume supports it. The market must close above 3281 to break the downtrend established since 3439 [5][8]. Support and Resistance Levels - Key resistance levels are identified at 3285, 3297, and strong resistance between 3319 and 3342. Support levels are at 3258, 3247, with strong support between 3233 and 3193 [11]. - The critical threshold for market strength is at 3307, with various levels indicating bullish or bearish dominance based on closing prices [10][9]. Trading Strategy - The recommended trading strategy involves oscillating between the upper and lower gaps, with a focus on filling the upper gap for bullish positions and the lower gap for bearish positions [7].

Group 1 - The market is warned of a potential "Black Monday" reminiscent of the 1987 crash, with significant declines in major indices [1][3] - On April 4, the S&P 500 index fell nearly 6%, marking its largest single-day drop since March 16, 2020, and is down 17% from its February peak [1] - The Dow Jones Industrial Average dropped 5.5%, the largest single-day decline since June 11, 2020, while the Nasdaq Composite fell 5.82%, entering a technical bear market with a cumulative drop of over 20% from its December peak [1] Group 2 - Despite the recent declines, U.S. stock valuations remain significantly overvalued, with the Buffett Indicator at 170%, exceeding the historical trend line by 34.5 percentage points [2][6] - The Buffett Indicator measures the ratio of U.S. stock market capitalization to GDP, with the current Wilshire 5000 index at $50.559 trillion and the latest annualized GDP at $29.724 trillion [6] - UBS downgraded U.S. stocks from "attractive" to "neutral," citing potential economic recession and significant market declines if tariffs are not addressed [12] Group 3 - The possibility of a market circuit breaker is being discussed, which would halt trading if the S&P 500 index falls by certain thresholds [8][9][10] - The thresholds for circuit breakers are set at 7% (level 1), 13% (level 2), and 20% (level 3) declines, with specific point levels identified for the S&P 500 [11] Group 4 - Market expectations for Federal Reserve interest rate cuts have increased from three to five times within the year, with the next cut anticipated in May [14] - UBS forecasts U.S. GDP growth to slow to below 1%, with potential recession risks and inflation impacts from tariff policies complicating Fed decisions [14]

恒星币生态扩张与市场表现：技术整合驱动跨境金融革新 恒星网络近期完成多项战略升级，其核心协议SCP（恒星共识协议）通过联邦拜占庭算法实现4秒交易 确认，日均处理量突破500万笔。2025年3月，恒星发展基金会（SDF）宣布与DIA、Pelago Labs达成技 术合作，集成Lumina数据预言机系统，使代币化应收账款与USDC稳定币实现链上自动清算。与此同 时，Ondo Finance将USDY收益型稳定币引入恒星网络，通过XLM桥接资产提升跨境支付效率。市场交 易层面，XLM在XBIT、币安等平台的周交易量环比增长22%，其中机构账户占比提升至18%。链上数 据显示，XLM质押量突破12亿枚，年化收益率为4.8%，较以太坊质押收益高0.7个百分点。价格走势方 面，XLM自3月11日0.245美元启动上升通道，四次回踩趋势线后形成0.285美元强支撑，当前RSI指标处 于54中性区间，MACD呈多头收敛形态，若突破0.3美元心理关口，有望冲击0.33美元年度高位。 图片来源：币界网 来源：科普新视角 截至2025年3月28日，恒星币（XLM）实时价格约为0.28美元，市值87.5亿美元，位列第15位。近期 X ...

Company Overview - Arcuro Medical Ltd. is a portfolio company of The Trendlines Group, headquartered in Israel with operations in the U.S. [4] - The company specializes in developing and manufacturing minimally invasive orthopedic products, focusing on innovative medical devices [4]. - Arcuro Medical aims to improve patients' lives through game-changing technologies in sports medicine [4]. Investment Details - Varana Capital is the lead investor in Arcuro Medical's Series A financing round, which is currently open for additional investment [1]. - The funding will support Arcuro's growth and innovation in the medical device industry [1]. - Other notable investors in this round include Trendlines and Consensus Business Group [1]. Strategic Goals and Achievements - Arcuro Medical concluded 2024 with significant achievements, including the establishment of a new U.S. organization and hiring key sales leadership [5]. - The company added new U.S. and international distribution partners and achieved a significant product development milestone with the 510(k) submission of a new product line [5]. - Arcuro Medical surpassed 5,000 global SuperBall cases, positioning itself for substantial growth in 2025 [5]. Upcoming Events - Arcuro Medical will present at the MSK Innovations Pitch Event on January 8, 2025, providing insights into the company's vision and advancements [3].

Subscribers to Schaeffer's Weekend Trader options recommendation service received this GE commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters. Learn more about why Weekend Trader is one of our most popular options trading services.Shares of GE Aerospace (NYSE:GE) recently cleared their 2005 and 2017 highs, and are pulling back to their 20-week and 126-day moving averages, both of which have led to outsized gains. Concerning the latte ...

Core Insights - ElastiMed Ltd. has appointed Dr. Amir Belson to its Board of Directors, enhancing its leadership in the wearable medical device sector [1][4] - Dr. Belson brings extensive experience in the medical device industry, having founded and led several successful companies that were acquired by major players [2][3] - His appointment is timely as ElastiMed aims to bring its innovative compression therapy devices to market, targeting millions suffering from lymphatic and venous diseases [3][4] Company Overview - ElastiMed specializes in wearable medical devices designed to treat and manage lymphatic and venous diseases, focusing on innovation and patient empowerment [5] - The company is committed to improving patient outcomes and addressing health equity challenges while enhancing healthcare delivery at home [5][6] - ElastiMed is a portfolio company of The Trendlines Group Ltd. and has received funding from various sources, including the Israeli Innovation Authority and Horizon 2020 [6]

Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive TreatmentBROOKLYN, N.Y., Oct. 28, 2024 /PRNewswire/ -- Vensica Medical ("Vensica"), a pioneering urology therapeutics company, today announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its revolutionary treatment of overactive bladder (OAB) using botulinum t ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...